Octopamine hydrochloride is released under model code OC-HCl-PG-101 for solid oral dosage forms and OC-HCl-PG-102 for injectable preparation. The compound is the hydrochloride salt of 4-(2-amino-1-hydroxyethyl)phenol, identified by CAS 770-05-8, molecular formula C8H12ClNO2, and molar mass 189.64 g mol⁻¹. The oral grade is a white to off-white crystalline powder; the injectable grade is supplied as a low-endotoxin crystalline powder or as a filtered bulk solution according to the order. The salt form increases aqueous solubility relative to the free base, permitting aqueous wet granulation, direct compression, capsule filling, and injectable formulation without requiring strongly acidic vehicle systems. Because no harmonized pharmacopoeial monograph exists for octopamine hydrochloride in all jurisdictions, the release specification is assembled from general USP and Ph. Eur. chapters and justified under ICH Q6A. The material is controlled for identity, assay, related substances, residual solvents, elemental impurities, loss on drying, residue on ignition, and microbial quality.

The oral grade is non-sterile and is intended for tablet, capsule, and granule manufacture under 21 CFR 210/211 and ICH Q7. The injectable grade carries additional endotoxin and particulate matter controls and is released after aseptic or terminal sterilisation validation. The oral and injectable grades are not interchangeable without requalification because the injectable grade adds low-endotoxin processing, restricted bioburden, and container closure requirements. Differences from other phenethylamine salts are primarily structural: octopamine lacks the 3-hydroxy substituent of norepinephrine and the N-methyl substituent of synephrine, reducing catechol-related oxidative instability while retaining the β-hydroxyamine structure.

What Limits Direct Compression of Octopamine Hydrochloride at High Dose?

Direct compression of this API at high dose is constrained by flow and segregation rather than chemical instability. The hydrochloride salt is freely water-soluble, but the bulk crystal habit can produce a cohesive powder with a compressibility index above 25% when measured by USP<1174>; under these conditions, flow through a gravity hopper may be inconsistent, and tablet weight variability can exceed USP<905> limits if the press speed is not matched to the feed-frame capacity. A forced feed frame is preferred over a gravity feed frame on rotary tablet presses. Blending with 0.5–1.0% colloidal silicon dioxide and 0.5–2.0% magnesium stearate is used to reduce interparticulate cohesion; however, magnesium stearate above 2.0% can retard dissolution of compressed tablets. Dissolution is monitored by USP<711> Apparatus 2 at 50 rpm unless product-specific method validation supports a different rotation speed. Published direct compression data for octopamine hydrochloride is limited, so blend uniformity and compactibility must be evaluated on a formulation-specific basis. The compression run should include periodic weight, hardness, thickness, and friability checks per USP<1216>.

Wet Granulation, Roller Compaction and Drying Endpoint Control

When direct compression is not feasible because of high drug load or poor flow, wet granulation with an aqueous binder introduces a process conflict: the freely water-soluble API can partially dissolve during binder addition, migrate to the granule surface during drying, and create surface-enriched granules. On a production-scale high-shear mixer, this migration is visible as white surface films on drying trays and as punch filming during subsequent compression. To limit this, the binder fluid is prepared as a hydroalcoholic solution or a low-water binder is used; where water must be used, spray rate is reduced and granule moisture is monitored during the wet massing stage. The endpoint of wet granulation can be assessed by a torque sensor on the high-shear mixer and by sieve fraction analysis using Ph. Eur. 2.9.12. After drying, loss on drying is performed by USP<731>; a target moisture of ≤1.0% is typically applied for tablet and capsule formulations to prevent sticking. Roller compaction is an alternative for moisture-sensitive or heat-sensitive formulations; compact ribbon density is controlled by roll pressure and roll speed, but published roller compaction parameters for this API are limited. Granules from roller compaction may have a higher fines fraction, requiring screening below 840 µm before compression. If the API is formulated as a granule for sachet or oral suspension, particle size distribution is tested by Ph. Eur. 2.9.12; typical acceptance criteria include D90 not more than 850 µm for granules, but this limit is product-specific.

Capsule filling uses the same granulated or direct-blend intermediate. Filling equipment with auger or dosing-disc systems requires consistent powder density; bulk density and tapped density are measured by USP<616>, and the resulting Hausner ratio should remain below 1.25 for acceptable filling. Gelatin and hypromellose capsule shells are compatible with the dry powder, but hygroscopic components in the blend should be limited because capsule shells may lose or absorb moisture under RH 40–60% ambient conditions. Fill weight is monitored by in-process weight checks at 5–10% of total capsule count depending on line capability. Capsule-grade API does not require additional processing beyond lubrication and, where specified, a stability-compatible desiccant.

Release Specification Is Route-Dependent and Includes Residual Solvent Control

The release specification is route-dependent. Oral grade OC-HCl-PG-101 is controlled for identity, assay, related substances, residual solvents, elemental impurities, loss on drying, residue on ignition, bioburden, and specified organisms. The table below lists the representative controls for the oral grade; the injectable grade adds bacterial endotoxin and particulate matter testing described in the parenteral manufacturing section. Residual solvents are controlled by headspace gas chromatography under USP<467>; the manufacturing process avoids Class 1 solvents, and Class 2 solvent residues are limited according to the options in the chapter. Elemental impurities are risk-assessed under ICH Q3D and confirmed by USP<232>/USP<233>.

If a solvate or hydrate is manufactured, the 0.5% loss-on-drying limit must be redeveloped. The oral-grade bioburden limits above are typical for non-sterile API; the finished product manufacturer remains responsible for meeting dosage-form microbiological attributes under USP<1111>. In jurisdictions where no harmonized monograph exists, the API is released against a specification that applies general Ph. Eur. chapters. The finished product applicant must ensure that the specification is registered in the relevant marketing authorisation. The absence of a specific monograph does not waive stability testing under ICH Q1A(R2) or photostability testing under ICH Q1B. Where stability data are generated, long-term storage at 25°C/60% RH and accelerated storage at 40°C/75% RH are standard conditions. Because the molecule lacks a catechol group, discoloration is expected to be slower than with norepinephrine salts, but published comparative rate constants are limited. Avoid combination with strong oxidising agents and strong alkali. In solid dosage forms, contact with reducing sugars at elevated temperature may lead to Maillard-type degradation of the primary amine; such excipients should be avoided unless compatibility studies demonstrate acceptable impurity profiles.

Granule formulations intended for oral suspension require additional rheological testing of the reconstituted suspension. If the granule contains the API as the uncoated hydrochloride salt, dissolution in water may be immediate; if the API is coated with a polymethacrylate or ethylcellulose barrier, release can be modified. No specific dissolution standard applies to granules alone; finished product dissolution is established by USP<711> or Ph. Eur. 2.9.3. The analytical HPLC method should be validated under ICH Q2(R1) for specificity, linearity, accuracy, precision, and range before release testing.

When Octopamine Hydrochloride Is Specified for Injectable Manufacturing

For injectable applications, the API is processed in a controlled environment with final sterilisation or aseptic filtration. The hydrochloride salt is freely soluble in Water for Injection; the bulk solution is filtered through a 0.22 µm sterilising-grade polyethersulfone or polyvinylidene fluoride membrane. If terminal steam sterilisation at 121°C is considered, the time–temperature cycle must be validated because published thermal degradation data for octopamine hydrochloride is limited; aseptic filtration is therefore commonly used for clinical supplies. The solution pH is maintained with a citrate or acetate buffer to prevent pH drift; unbuffered solutions may show pH drift on storage. The maximum clinical dose must be used to calculate the endotoxin limit by the K/M formula of USP<85>, and the bulk API endotoxin release limit is set below that value. Particulate matter in the finished injection is tested by USP<788>; container closure integrity is maintained by USP<1207>. The injectable-grade API is packaged in sealed polyethylene inner bags with an outer aluminium laminate to limit moisture ingress and maintain low bioburden.

Sterile bulk solution may be lyophilised if the finished product requires a lyophilised powder. The lyophilisation cycle must avoid collapse temperature excursions; the collapse temperature is determined by freeze-drying microscopy, but published data for octopamine hydrochloride bulk solution is limited. Before lyophilisation, the solution is filtered through the same 0.22 µm sterilising-grade membrane. The injectable route adds a container closure system selection burden: elastomeric closures should be evaluated for extractables and leachables under ICH Q3D risk assessment and USP<1663> approaches, but the specific closure is final product dependent.

Comparing Stability, Salt Selection, and Processing Differences Across Phenethylamine Salts

The table compares the hydrochloride salt of octopamine with synephrine hydrochloride and norepinephrine hydrochloride. The key processing difference is the absence of a catechol group in octopamine and synephrine, which reduces aerobic oxidation and eliminates the mandatory use of metal-chelating antioxidants required for norepinephrine formulations. The absence of an N-methyl substituent in octopamine distinguishes it from synephrine and may affect both the solid-state cohesion and the receptor-binding profile, but published comparative formulation data for this specific configuration is limited.